PLG and COVID-19: A combination of elevated levels of PAI-1and low levels of plasminogen was reported in 23.60% of the hypofibrinolysis patients, while hyperfibrinolysis was reported in 14.59% of the patients, with an increase and decrease in the α2AP and tPA levels, thereby making them more suitable candidates for predicting hyperfibrinolysis in COVID-19 patients; this is illustrated in Table 4.